{"contentid": 488750, "importid": NaN, "name": "BlueRock and Senti Bio to work together on advanced therapies", "introduction": "Cell therapy specialist and Bayer subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio).", "content": "<p>Cell therapy specialist and Bayer (BAYN: DE) subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio).</p>\n<p>The deal will see Senti Bio&rsquo;s gene circuit technology being applied to the development of BlueRock&rsquo;s next-generation engineered cell therapies.</p>\n<p>Senti Bio is working on engineering gene circuits to reprogram cells so that they are able to sense inputs and interact with their cellular environments in a different way.</p>\n<p>Ultimately, the firm hopes to create an innovative type of programmable regenerative medicine.</p>\n<h2>Collaboration</h2>\n<p>The collaboration has the potential for a broad range of applications in different therapeutic areas, including but not limited to neurology, cardiology and immunology within the field of regenerative medicine.</p>\n<p>Senti Bio will take the lead on designing, building and testing certain &ldquo;smart sensors&rdquo; and &ldquo;regulator dials&rdquo; for use in BlueRock&rsquo;s regenerative medicine product candidates.</p>\n<p>BlueRock will receive an option to license gene circuits emerging from the collaboration for cell therapy products in specified indications.</p>\n<p>Should the company choose to exercise its option, it will become responsible for conducting preclinical, clinical and commercialization activities from that point on.</p>\n<p>Chief executive Emile Nuwaysir said: &ldquo;There is tremendous opportunity at the intersection of cell, gene and systems biology. With control of all three axes, we believe we can further engineer the cell&rsquo;s inherent potential to integrate multiple physiologic inputs to produce powerful therapeutic benefit in vivo.&rdquo;</p>", "date": "2021-05-26 15:47:00", "meta_title": NaN, "meta_keywords": "Senti, gene, BlueRock, cell, work, circuit, technology, therapy, company, therapies, advanced, specialist, Bayer, subsidiary, Therapeutics, USA-based, BAYN", "meta_description": "Cell therapy specialist and Bayer subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio) on the latter", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-26 15:37:16", "updated": "2021-05-26 15:49:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/bluerock-and-senti-bio-to-work-together-on-advanced-therapies", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lab_biotech_test_big.jpg", "image2id": "lab_biotech_test_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy", "topic_tag": "Deals, Licensing, Research", "geography_tag": "Germany, USA", "company_tag": "Bayer, BlueRock Therapeutics, Senti Biosciences", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-26 15:47:00"}